Tumor suppressor function of PGP9.5 is associated with epigenetic regulation in prostate cancer - Novel predictor of biochemical recurrence after radical surgery

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 3, 2012, Pages 487-496

  Mitsui, Yozo ^a   Shiina, Hiroaki ^a   Hiraki, Miho ^a   Arichi, Naoko ^a   Hiraoka, Takeo ^a   Sumura, Masahiro ^a   Honda, Satoshi ^a   Yasumoto, Hiroaki ^a   Igawa, Mikio ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; MESSENGER RNA; MOLECULAR MARKER; SMALL INTERFERING RNA;

AGED; ARTICLE; CANCER CELL CULTURE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER TISSUE; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENETIC ANALYSIS; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIVARIATE ANALYSIS; PATHOGENESIS; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN G PRODUCT 9.5 GENE; RNA TRANSCRIPTION; TUMOR SUPPRESSOR GENE;

AGED; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; NEOPLASM RECURRENCE, LOCAL; PROMOTER REGIONS, GENETIC; PROSTATECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; UBIQUITIN THIOLESTERASE;

EID: 84859419068     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0970     Document Type: Article

References (34)

1. Shao YH, Demissie K, Shih W, Mehta AR, Stein MN, Roberts CB, et al. Contemporary risk profile of prostate cancer in the United State. J Natl Cancer Inst 2009;101:1280-3.
2. Meng MV, Carroll PRTreatment of locally advanced prostate cancer. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Wein AJ editors. Campbell-Walsh urology. 9th ed. Philadelphia, PA: WB Saunders; 2007. p. 3053-68.
3. Potters L, Klein EA, Kattan MW, Reddy CA, Ciezki JP, Reuther AM, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beamradiotherapy, or permanent seed implantation. Radiother Oncol 2004;71:29-31.
4. Spahn M, Weiss C, Bader P, Ströbel P, Gerharz EW, Kneitz B, et al. Long-term outcome of patients with high-risk prostate cancer following radical prostatectomy and stage-dependent adjuvant androgen deprivation. Urol Int 2010;84:164-73.
5. Suzuki K, Nakano K, Morita T. Outcome of adjuvant radiotherapy after radical prostatectomy for prostate cancer patients. Urol Int 2010;84:382-7.
6. Dillman RO, Hafer R, Cox C, McClure SE. Overall survival benefit from postoperative radiation therapy for organ-confined, margin-positive prostate cancer. Int J Radiat Oncol Biol Phys 2011;79:719-23.
7. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001;28:555-65. (Pubitemid 32916759)
8. Wilkinson K, Lee K, Deshpande S, Duerksen-Hughes P, Boss J, Pohl J. The neuron-specific protein PGP9.5 is a ubiquitin carboxy-terminal hydrolase. Science 1989;246:670-3. (Pubitemid 19283361)
9. Liu Y, Fallon L, Lashuel H, Liu Z, Lansbury P Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111:209-18. (Pubitemid 35292441)
10. Aumüller G, Renneberg H, Leonhardt M, Lilja H, Abrahamsson PA. Localization of protein gene product 9.5 immunoreactivity in derivatives of the human Wolffian duct and in prostate cancer. Prostate 1999;38:261-7. (Pubitemid 29119791)
11. Martín R, Fraile B, Peinado F, Arenas MI, Elices M, Alonso L, et al. Immunohistochemical localization of protein gene product 9.5, ubiquitin, and neuropeptide Y immunoreactivities in epithelial and neuroendocrine cells from normal and hyperplastic human prostate. J Histochem Cytochem 2000;48:1121-30. (Pubitemid 30640196)
12. Leiblich A, Cross SS, Catto JW, Pesce G, Hamdy FC, Rehman I. Human prostate cancer cells express neuroendocrine cell markers PGP9.5 and chromogranin A. Prostate 2007;67:1761-9. (Pubitemid 350228728)
13. Jones P. DNA methylation and cancer. Oncogene 2002;21:5358-60. (Pubitemid 34983472)
14. Sidransky D. Emerging molecular makers of cancer. Nat Rev Cancer 2002;2:210-9.
15. Brait M, Begum S, Carvalho AL, Dasgupta S, Vettore AL, Czerniak B, et al. Aberrant promoter methylation of multiple genes during pathogenesis of bladder cancer. Cancer Epidemiol Biomarkers Prev 2008;17:2786-94.
16. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-througput microarrays. Cancer Res 2003;63:3735-42. (Pubitemid 36793060)
17. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, et al. PGP9.5 promotor methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65:4963-8. (Pubitemid 40740837)
18. Yamashita K, Park HL, Kim MS, Osada M, Tokumaru Y, Inoue H, et al. PGP9.5 methylation in diffuse-type gastric cancer. Cancer Res 2006;66:3921-7.
19. Tokumaru Y, Yamashita K, Kim MS, Park HL, Osada M, Mori M, et al. The role of PGP9.5 as a tumor suppressor gene in human cancer. Int J Cancer 2008;123:753-9. (Pubitemid 352032399)
20. The Japanese Urological Association and the Japanese Society of Pathology. General rules for clinical and pathological studies on prostate cancer. 2nd ed. Tokyo, Japan: Kanahara-Shuppan; 1992.
21. Gleason DF. Veteran's Administration Cooperative Urological Research Group. Histological grading and clinical staging of prostatic carcinoma. In: Tannenbaum M, editor. Urologic pathology. Philadelphia, PA: Lea & Febiger; 1977. p. 171-97.
22. Shigeno K, Igawa M, Shiina H, Wada H, Yoneda T. The role of colour Doppler ultrasonography in detecting prostate cancer. BJU Int 2000;86:229-33. (Pubitemid 30621222)
23. Dahiya R, Lee C, McCarville J, Hu W, Kaur G, Deng G. High frequency of genetic instability of microsatellites in human prostatic adenocarcinoma. Int J Cancer 1997;72:762-7. (Pubitemid 27431517)
24. Potter E, Braun S, Lehmann U, Brabant G. Molecular cloning of a functional promoter of the human plakoglobin gene. Eur J Endocrinol 2001;145:625-33. (Pubitemid 33061909)
25. Grube D: The endocrine cells of the digestive system: amines, peptides, and modes of action. Anat Embryol 1986;175:151-62.
26. Isshiki S, Akakura K, Komiya A, Suzuki H, Kamiya N, Ito H. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002;167:512-5. (Pubitemid 34074517)
27. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004;45:586-92. (Pubitemid 38481685)
28. Mc William LJ, Manson C, George NJ. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997;80:287-90. (Pubitemid 28318898)
29. Huss WJ, Gregory CW, Smith GJ. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. Prostate 2004;60:91-7. (Pubitemid 38758574)
30. Jin RJ,Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB. NE-10 neuroendocrine cancer promotes the LNCap xenograft growth in castrated mice. Cancer Res 2004;64:5489-95. (Pubitemid 39006573)
31. Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, et al. Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol 2010;134:71-9.
32. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002;8:192-5. (Pubitemid 34101477)
33. Howell VM, Gill A, Clarkson A, Nelson AE, Dunne R, Delbridge LW, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab 2009;94:434-41.
34. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-74.